C1q, antibodies and anti-C1q autoantibodies

Molecular Immunology

Volumn 68, Issue 1, 2015, Pages 6-13

  Beurskens, Frank J ^a   van Schaarenburg, Rosanne A ^b   Trouw, Leendert A ^b  

^a GENMAB   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibodies; C1q; Complement

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; AUTOANTIGEN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C3B RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; SPHINGOLIPID ACTIVATOR PROTEIN 2; ANTIGEN ANTIBODY COMPLEX; AUTOANTIBODY;

ADAPTIVE IMMUNITY; AMINO TERMINAL SEQUENCE; ANTIGEN ANTIBODY COMPLEX; CARBOXY TERMINAL SEQUENCE; CELL MATURATION; COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; DENDRITIC CELL; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; AUTOIMMUNE DISEASE; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; PATHOLOGY; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; AUTOIMMUNE DISEASES; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; DENDRITIC CELLS; GENE EXPRESSION REGULATION; HUMANS; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MACROPHAGES; PROTEIN MULTIMERIZATION; SIGNAL TRANSDUCTION;

EID: 84952636817     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.05.010     Document Type: Review

References (135)

1. Agnello V., Koffler D., Eisenberg J.W., Winchester R.J., Kundel H.G. C1g precipitins in the sera of patients with systemic lupus erythematosus and other hypocomplementemic states: characterization of high and low molecular weight types. J. Exp. Med. 1971, 134:228s-241s.
2. Antes U., Heinz H.P., Loos M. Evidence for the presence of autoantibodies to the collagen-like portion of C1q in systemic lupus erythematosus. Arthritis Rheum. 1988, 31:457-464.
3. Arason G.J., Steinsson K., Kolka R., Vikingsdottir T., D'Ambrogio M.S., Valdimarsson H. Patients with systemic lupus erythematosus are deficient in complement-dependent prevention of immune precipitation. Rheumatology (Oxford) 2004, 43:783-789.
4. Arnold J.N., Wormald M.R., Suter D.M., Radcliffe C.M., Harvey D.J., Dwek R.A., Rudd P.M., Sim R.B. Human serum IgM glycosylation: identification of glycoforms that can bind to mannan-binding lectin. J. Biol. Chem. 2005, 280:29080-29087.
5. Balestrieri G., Pagani D., Tincani A. Solubilization of immune complexes and inhibition of immune precipitation in SLE sera. J. Clin. Lab Immunol. 1983, 12:147-150.
6. Baruah P., Dumitriu I.E., Malik T.H., Cook H.T., Dyson J., Scott D., Simpson E., Botto M. C1q enhances IFN-gamma production by antigen-specific T cells via the CD40 costimulatory pathway on dendritic cells. Blood 2009, 113:3485-3493.
7. Baruah P., Simpson E., Dumitriu I.E., Derbyshire K., Coe D., Addey C., Dyson J., Chai J.G., Cook T., Scott D., Botto M. Mice lacking C1q or C3 show accelerated rejection of minor H disparate skin grafts and resistance to induction of tolerance. Eur. J. Immunol. 2010, 40:1758-1767.
8. Borsos T., Rapp H.J. Complement fixation on cell surfaces by 19S and 7S antibodies. Science 1965, 150:505-506.
9. Bossi F., Tripodo C., Rizzi L., Bulla R., Agostinis C., Guarnotta C., Munaut C., Baldassarre G., Papa G., Zorzet S., Ghebrehiwet B., Ling G.S., Botto M., Tedesco F. C1q as a unique player in angiogenesis with therapeutic implication in wound healing. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:4209-4214.
10. Botto M., Dell'Agnola C., Bygrave A.E., Thompson E.M., Cook H.T., Petry F., Loos M., Pandolfi P.P., Walport M.J. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 1998, 19:56-59.
11. Burton D.R. Immunoglobulin G: functional sites. Mol. Immunol. 1985, 22:161-206.
12. Burton D.R. Is IgM-like dislocation a common feature of antibody function?. Immunol. Today 1986, 7:165-167.
13. Burton D.R. Antibody: the flexible adaptor molecule. Trends Biochem. Sci. 1990, 15:64-69.
14. Cao C.W., Li P., Luan H.X., Chen W., Li C.H., Hu C.J., Zhang S.L., Zeng X.F., Zhang F.C., Li Y.Z., Zeng C.Q. Association study of C1qA polymorphisms with systemic lupus erythematosus in a Han population. Lupus 2012, 21:502-507.
15. Carroll M.C. The lupus paradox. Nat. Genet. 1998, 19:3-4.
16. Castellano G., Trouw L.A., Fiore N., Daha M.R., Schena F.P., van K.C. Infiltrating dendritic cells contribute to local synthesis of C1q in murine and human lupus nephritis. Mol. Immunol. 2010, 47:2129-2137.
17. Castellano G., Woltman A.M., Nauta A.J., Roos A., Trouw L.A., Seelen M.A., Schena F.P., Daha M.R., van K.C. Maturation of dendritic cells abrogates C1q production in vivo and in vitro. Blood 2004, 103:3813-3820.
18. Castellano G., Woltman A.M., Schena F.P., Roos A., Daha M.R., van K.C. Dendritic cells and complement: at the cross road of innate and adaptive immunity. Mol. Immunol. 2004, 41:133-140.
19. Clarke E.V., Weist B.M., Walsh C.M., Tenner A.J. Complement protein C1q bound to apoptotic cells suppresses human macrophage and dendritic cell-mediated Th17 and Th1 T cell subset proliferation. J. Leukocyte Biol. 2015, 97:147-160.
20. Collins C., Tsui F.W., Shulman M.J. Differential activation of human and guinea pig complement by pentameric and hexameric IgM. Eur. J. Immunol. 2002, 32:1802-1810.
21. Coremans I.E., Daha M.R., van der Voort E.A., Muizert Y., Halma C., Breedveld F.C. Antibodies against C1q in anti-glomerular basement membrane nephritis. Clin. Exp. Immunol. 1992, 87:256-260.
22. Coremans I.E., Daha M.R., van der Voort E.A., Siegert C.E., Breedveld F.C. Subclass distribution of IgA and IgG antibodies against Clq in patients with rheumatic diseases. Scand. J. Immunol. 1995, 41:391-397.
23. Coremans I.E., Spronk P.E., Bootsma H., Daha M.R., van der Voort E.A., Kater L., Breedveld F.C., Kallenberg C.G. Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am. J. Kidney Dis. 1995, 26:595-601.
24. Czajkowsky D.M., Shao Z. The human IgM pentamer is a mushroom-shaped molecule with a flexural bias. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14960-14965.
25. Czop J., Nussenzweig V. Studies on the mechanism of solubilization of immune precipitates by serum. J. Exp. Med. 1976, 143:615-630.
26. Daha N.A., Banda N.K., Roos A., Beurskens F.J., Bakker J.M., Daha M.R., Trouw L.A. Complement activation by (auto-) antibodies. Mol. Immunol. 2011, 48:1656-1665.
27. Davies A.M., Rispens T., Ooijevaar-de H.P., Gould H.J., Jefferis R., Aalberse R.C., Sutton B.J. Structural determinants of unique properties of human IgG4-Fc. J. Mol. Biol. 2014, 426:630-644.
28. Davies K.A. Complement. Baillieres Clin. Haematol. 1991, 4:927-955.
29. Dechant M., Valerius T. IgA antibodies for cancer therapy. Crit Rev. Oncol. Hematol. 2001, 39:69-77.
30. Devaraju P., Reni B.N., Gulati R., Mehra S., Negi V.S. Complement C1q and C2 polymorphisms are not risk factors for SLE in Indian Tamils. Immunobiology 2014, 219:465-468.
31. Diebolder C.A., Beurskens F.J., de Jong R.N., Koning R.I., Strumane K., Lindorfer M.A., Voorhorst M., Ugurlar D., Rosati S., Heck A.J., van de Winkel J.G., Wilson I.A., Koster A.J., Taylor R.P., Saphire E.O., Burton D.R., Schuurman J., Gros P., Parren P.W. Complement is activated by IgG hexamers assembled at the cell surface. Science 2014, 343:1260-1263.
32. Dragon-Durey M.A., Blanc C., Marinozzi M.C., van Schaarenburg R.A., Trouw L.A. Autoantibodies against complement components and functional consequences. Mol. Immunol. 2013, 56:213-221.
33. Eggleton P., Ukoumunne O.C., Cottrell I., Khan A., Maqsood S., Thornes J., Perry E., Isenberg D. Autoantibodies against C1q as a diagnostic measure of lupus nephritis: systematic review and meta-analysis. J. Clin. Cell Immunol. 2014, 5:210.
34. Feinstein A., Richardson N., Taussig M.I. Immunoglobulin flexibility in complement activation. Immunol. Today 1986, 7:169-174.
35. Ferry H., Potter P.K., Crockford T.L., Nijnik A., Ehrenstein M.R., Walport M.J., Botto M., Cornall R.J. Increased positive selection of B1 cells and reduced B cell tolerance to intracellular antigens in c1q-deficient mice. J. Immunol. 2007, 178:2916-2922.
36. Fossati-Jimack L., Cortes-Hernandez J., Norsworthy P.J., Walport M.J., Cook H.T., Botto M. C1q deficiency promotes the production of transgenic-derived IgM and IgG3 autoantibodies in anti-DNA knock-in transgenic mice. Mol. Immunol. 2008, 45:787-795.
37. Gal P., Dobo J., Zavodszky P., Sim R.B. Early complement proteases: C1r, C1s and MASPs. A structural insight into activation and functions. Mol. Immunol. 2009, 46:2745-2752.
38. Golan M.D., Burger R., Loos M. Conformational changes in C1q after binding to immune complexes: detection of neoantigens with monoclonal antibodies. J. Immunol. 1982, 129:445-447.
39. Groeneveld T.W., Oroszlan M., Owens R.T., Faber-Krol M.C., Bakker A.C., Arlaud G.J., McQuillan D.J., Kishore U., Daha M.R., Roos A. Interactions of the extracellular matrix proteoglycans decorin and biglycan with C1q and collectins. J. Immunol. 2005, 175:4715-4723.
40. Hiemstra P.S., Gorter A., Stuurman M.E., van Es L.A., Daha M.R. Activation of the alternative pathway of complement by human serum IgA. Adv. Exp. Med. Biol. 1987, 216B:1297-1302.
41. Hogarth M.B., Norsworthy P.J., Allen P.J., Trinder P.K., Loos M., Morley B.J., Walport M.J., Davies K.A. Autoantibodies to the collagenous region of C1q occur in three strains of lupus-prone mice. Clin. Exp. Immunol. 1996, 104:241-246.
42. Horvath L., Czirjak L., Fekete B., Jakab L., Prohaszka Z., Cervenak L., Romics L., Singh M., Daha M.R., Fust G. Levels of antibodies against C1q and 60 kDa family of heat shock proteins in the sera of patients with various autoimmune diseases. Immunol. Lett. 2001, 75:103-109.
43. Hughes-Jones N.C., Gardner B. The reaction between the complement subcomponent C1q, IgG complexes and polyionic molecules. Immunology 1978, 34:459-463.
44. Jiang H.X., Siegel J.N., Gewurz H. Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q. J. Immunol. 1991, 146:2324-2330.
45. Johansen F.E., Braathen R., Brandtzaeg P. Role of J chain in secretory immunoglobulin formation. Scand. J. Immunol. 2000, 52:240-248.
46. Kerr M.A. The structure and function of human IgA. Biochem. J. 1990, 271:285-296.
47. Kishore U., Gaboriaud C., Waters P., Shrive A.K., Greenhough T.J., Reid K.B., Sim R.B., Arlaud G.J. C1q and tumor necrosis factor superfamily: modularity and versatility. Trends Immunol. 2004, 25:551-561.
48. Kohro-Kawata J., Wener M.H., Mannik M. The effect of high salt concentration on detection of serum immune complexes and autoantibodies to C1q in patients with systemic lupus erythematosus. J. Rheumatol. 2002, 29:84-89.
49. Korb L.C., Ahearn J.M. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J. Immunol. 1997, 158:4525-4528.
50. Krumdieck R., Hook M., Rosenberg L.C., Volanakis J.E. The proteoglycan decorin binds C1q and inhibits the activity of the C1 complex. J. Immunol. 1992, 149:3695-3701.
51. Labrijn A.F., Aalberse R.C., Schuurman J. When binding is enough: nonactivating antibody formats. Curr. Opin. Immunol. 2008, 20:479-485.
52. Mahler M., van Schaarenburg R.A., Trouw L.A. Anti-C1q autoantibodies, novel tests, and clinical consequences. Front. Immunol. 2013, 4:117.
53. Manderson A.P., Botto M., Walport M.J. The role of complement in the development of systemic lupus erythematosus. Annu. Rev. Immunol. 2004, 22:431-456.
54. Marquart H.V., Schejbel L., Sjoholm A., Martensson U., Nielsen S., Koch A., Svejgaard A., Garred P. C1q deficiency in an Inuit family: identification of a new class of C1q disease-causing mutations. Clin. Immunol. 2007, 124:33-40.
55. Martens H.A., Zuurman M.W., de Lange A.H., Nolte I.M., van der S.G., Navis G.J., Kallenberg C.G., Seelen M.A., Bijl M. Analysis of C1q polymorphisms suggests association with systemic lupus erythematosus, serum C1q and CH50 levels and disease severity. Ann. Rheum. Dis. 2009, 68:715-720.
56. Matrat A., Veysseyre-Balter C., Trolliet P., Villar E., Dijoud F., Bienvenu J., Fabien N. Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares. Lupus 2011, 20:28-34.
57. Melis J.P., Strumane K., Ruuls S.R., Beurskens F.J., Schuurman J., Parren P.W. Complement in therapy and disease: regulating the complement system with antibody-based therapeutics. Mol. Immunol. 2015, 67:117-130.
58. Meyer O.C., Nicaise-Roland P., Cadoudal N., Grootenboer-Mignot S., Palazzo E., Hayem G., Dieude P., Chollet-Martin S. Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus. Arthritis Res. Ther. 2009, 11:R87.
59. Miller G.W., Nussenzweig V. A new complement function: solubilization of antigen-antibody aggregates. Proc. Natl. Acad. Sci. U. S. A. 1975, 72:418-422.
60. Mitchell D.A., Pickering M.C., Warren J., Fossati-Jimack L., Cortes-Hernandez J., Cook H.T., Botto M., Walport M.J. C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J. Immunol. 2002, 168:2538-2543.
61. Mok C.C., Ho L.Y., Leung H.W., Wong L.G. Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus. Transl. Res. 2010, 156:320-325.
62. Moller N.P., Steensgaard J. Fc-mediated immune precipitation. II. Analysis of precipitating immune complexes by rate-zonal ultracentrifugation. Immunology 1979, 38:641-648.
63. Moroni G., Trendelenburg M., Del P.N., Quaglini S., Raschi E., Panzeri P., Testoni C., Tincani A., Banfi G., Balestrieri G., Schifferli J.A., Meroni P.L., Ponticelli C. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am. J. Kidney Dis. 2001, 37:490-498.
64. Moura C.G., Mangueira C.L., Cruz L.A., Cruz C.M. Negative anti-C1q antibody titers may influence therapeutic decisions and reduce the number of renal biopsies in systemic lupus erythematosus. Nephron Clin. Pract. 2011, 118:c355-c360.
65. Muller R., Grawert M.A., Kern T., Madl T., Peschek J., Sattler M., Groll M., Buchner J. High-resolution structures of the IgM Fc domains reveal principles of its hexamer formation. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:10183-10188.
66. Naama J.K., Hamilton A.O., Yeung-Laiwah A.C., Whaley K. Prevention of immune precipitation by purified classical pathway complement components. Clin. Exp. Immunol. 1984, 58:486-492.
67. Naama J.K., Niven I.P., Zoma A., Mitchell W.S., Whaley K. Complement, antigen-antibody complexes and immune complex disease. J. Clin. Lab Immunol. 1985, 17:59-67.
68. Naito A.T., Sumida T., Nomura S., Liu M.L., Higo T., Nakagawa A., Okada K., Sakai T., Hashimoto A., Hara Y., Shimizu I., Zhu W., Toko H., Katada A., Akazawa H., Oka T., Lee J.K., Minamino T., Nagai T., Walsh K., Kikuchi A., Matsumoto M., Botto M., Shiojima I., Komuro I. Complement c1q activates canonical wnt signaling and promotes aging-related phenotypes. Cell 2012, 149:1298-1313.
69. Namjou B., Gray-McGuire C., Sestak A.L., Gilkeson G.S., Jacob C.O., Merrill J.T., James J.A., Wakeland E.K., Li Q.Z., Langefeld C.D., Divers J., Ziegler J., Moser K.L., Kelly J.A., Kaufman K.M., Harley J.B. Evaluation of C1q genomic region in minority racial groups of lupus. Genes Immun. 2009, 10:517-524.
70. Nash J.T., Taylor P.R., Botto M., Norsworthy P.J., Davies K.A., Walport M.J. Immune complex processing in C1q-deficient mice. Clin. Exp. Immunol. 2001, 123:196-202.
71. Nauta A.J., Castellano G., Xu W., Woltman A.M., Borrias M.C., Daha M.R., van K.C., Roos A. Opsonization with C1q and mannose-binding lectin targets apoptotic cells to dendritic cells. J. Immunol. 2004, 173:3044-3050.
72. Nauta A.J., Raaschou-Jensen N., Roos A., Daha M.R., Madsen H.O., Borrias-Essers M.C., Ryder L.P., Koch C., Garred P. Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur. J. Immunol. 2003, 33:2853-2863.
73. Nauta A.J., Trouw L.A., Daha M.R., Tijsma O., Nieuwland R., Schwaeble W.J., Gingras A.R., Mantovani A., Hack E.C., Roos A. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur. J. Immunol. 2002, 32:1726-1736.
74. Orbai A.M., Truedsson L., Sturfelt G., Nived O., Fang H., Alarcon G.S., Gordon C., Merrill J., Fortin P.R., Bruce I.N., Isenberg D.A., Wallace D.J., Ramsey-Goldman R., Bae S.C., Hanly J.G., Sanchez-Guerrero J., Clarke A.E., Aranow C.B., Manzi S., Urowitz M.B., Gladman D.D., Kalunian K.C., Costner M.I., Werth V.P., Zoma A., Bernatsky S., Ruiz-Irastorza G., Khamashta M.A., Jacobsen S., Buyon J.P., Maddison P., Dooley M.A., van Vollenhoven R.F., Ginzler E., Stoll T., Peschken C., Jorizzo J.L., Callen J.P., Lim S.S., Fessler B.J., Inanc M., Kamen D.L., Rahman A., Steinsson K., Franks A.G., Sigler L., Hameed S., Pham N., Brey R., Weisman M.H., McGwin G., Magder L.S., Petri M. Anti-C1q antibodies in systemic lupus erythematosus. Lupus 2015, 24:42-49.
75. Papp K., Vegh P., Hobor R., Szittner Z., Voko Z., Podani J., Czirjak L., Prechl J. Immune complex signatures of patients with active and inactive SLE revealed by multiplex protein binding analysis on antigen microarrays. PLoS ONE 2012, 7:e44824.
76. Peerschke E.I., Ghebrehiwet B. cC1qR/CR and gC1qR/p33: observations in cancer. Mol. Immunol. 2014, 61:100-109.
77. Perkins S.J., Nealis A.S., Sutton B.J., Feinstein A. Solution structure of human and mouse immunoglobulin M by synchrotron X-ray scattering and molecular graphics modelling. A possible mechanism for complement activation. J. Mol. Biol. 1991, 221:1345-1366.
78. Petry F. Molecular basis of hereditary C1q deficiency. Immunobiology 1998, 199:286-294.
79. Potlukova E., Jiskra J., Limanova Z., Kralikova P., Smutek D., Mareckova H., Antosova M., Trendelenburg M. Autoantibodies against complement C1q correlate with the thyroid function in patients with autoimmune thyroid disease. Clin. Exp. Immunol. 2008, 153:96-101.
80. Prohaszka Z., Daha M.R., Susal C., Daniel V., Szlavik J., Banhegyi D., Nagy K., Varkonyi V., Horvath A., Ujhelyi E., Toth F.D., Uray K., Hudecz F., Fust G. C1q autoantibodies in HIV infection: correlation to elevated levels of autoantibodies against 60-kDa heat-shock proteins. Clin. Immunol. 1999, 90:247-255.
81. Racila D.M., Sontheimer C.J., Sheffield A., Wisnieski J.J., Racila E., Sontheimer R.D. Homozygous single nucleotide polymorphism of the complement C1QA gene is associated with decreased levels of C1q in patients with subacute cutaneous lupus erythematosus. Lupus 2003, 12:124-132.
82. Racila E., Link B.K., Weng W.K., Witzig T.E., Ansell S., Maurer M.J., Huang J., Dahle C., Halwani A., Levy R., Weiner G.J. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin. Cancer Res. 2008, 14:6697-6703.
83. Racila E., Racila D.M., Ritchie J.M., Taylor C., Dahle C., Weiner G.J. The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement. Immunogenetics 2006, 58:1-8.
84. Radanova M., Vasilev V., Deliyska B., Kishore U., Ikonomov V., Ivanova D. Anti-C1q autoantibodies specific against the globular domain of the C1qB-chain from patient with lupus nephritis inhibit C1q binding to IgG and CRP. Immunobiology 2012, 217:684-691.
85. Radanova M., Vasilev V., Dimitrov T., Deliyska B., Ikonomov V., Ivanova D. Association of rs172378 C1q gene cluster polymorphism with lupus nephritis in Bulgarian patients. Lupus 2015, 24:280-289.
86. Rafiq S., Frayling T.M., Vyse T.J., Cunninghame Graham D.S., Eggleton P. Assessing association of common variation in the C1Q gene cluster with systemic lupus erythematosus. Clin. Exp. Immunol. 2010, 161:284-289.
87. Randall T.D., King L.B., Corley R.B. The biological effects of IgM hexamer formation. Eur. J. Immunol. 1990, 20:1971-1979.
88. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11:785-797.
89. Roos A., Bouwman L.H., van Gijlswijk-Janssen D.J., Faber-Krol M.C., Stahl G.L., Daha M.R. Human IgA activates the complement system via the mannan-binding lectin pathway. J. Immunol. 2001, 167:2861-2868.
90. Roos A., Nauta A.J., Broers D., Faber-Krol M.C., Trouw L.A., Drijfhout J.W., Daha M.R. Specific inhibition of the classical complement pathway by C1q-binding peptides. J. Immunol. 2001, 167:7052-7059.
91. Saadoun D., Sadallah S., Trendelenburg M., Limal N., Sene D., Piette J.C., Schifferli J.A., Cacoub P. Anti-C1q antibodies in hepatitis C virus infection. Clin. Exp. Immunol. 2006, 145:308-312.
92. Schaller M., Bigler C., Danner D., Ditzel H.J., Trendelenburg M. Autoantibodies against C1q in systemic lupus erythematosus are antigen-driven. J. Immunol. 2009, 183:8225-8231.
93. Schifferli J.A., Woo P., Peters D.K. Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways. Clin. Exp. Immunol. 1982, 47:555-562.
94. Seelen M.A., Roos A., Daha M.R. Role of complement in innate and autoimmunity. J. Nephrol. 2005, 18:642-653.
95. Seelen M.A., Roos A., Wieslander J., Mollnes T.E., Sjoholm A.G., Wurzner R., Loos M., Tedesco F., Sim R.B., Garred P., Alexopoulos E., Turner M.W., Daha M.R. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J. Immunol. Methods 2005, 296:187-198.
96. Seelen M.A., Trouw L.A., Daha M.R. Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Curr. Opin. Nephrol. Hypertens. 2003, 12:619-624.
97. Siegert C., Daha M., Westedt M.L., van der Voort E., Breedveld F. IgG autoantibodies against C1q are correlated with nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus. J. Rheumatol. 1991, 18:230-234.
98. Siegert C.E., Daha M.R., Halma C., van der Voort E.A., Breedveld F.C. IgG and IgA autoantibodies to C1q in systemic and renal diseases. Clin. Exp. Rheumatol. 1992, 10:19-23.
99. Siegert C.E., Daha M.R., Swaak A.J., van der Voort E.A., Breedveld F.C. The relationship between serum titers of autoantibodies to C1q and age in the general population and in patients with systemic lupus erythematosus. Clin. Immunol. Immunopathol. 1993, 67:204-209.
100. Siegert C.E., Daha M.R., van der Voort E.A., Breedveld F.C. IgG and IgA antibodies to the collagen-like region of C1q in rheumatoid vasculitis. Arthritis Rheum. 1990, 33:1646-1654.
101. Sinico R.A., Rimoldi L., Radice A., Bianchi L., Gallelli B., Moroni G. Anti-C1q autoantibodies in lupus nephritis. Ann. N. Y. Acad. Sci. 2009, 1173:47-51.
102. Sjoberg A., Onnerfjord P., Morgelin M., Heinegard D., Blom A.M. The extracellular matrix and inflammation: fibromodulin activates the classical pathway of complement by directly binding C1q. J. Biol. Chem. 2005, 280:32301-32308.
103. Sledge C.R., Bing D.H. Binding properties of the human complement protein Clq. J. Biol. Chem. 1973, 248:2818-2823.
104. Son M., Santiago-Schwarz F., Al-Abed Y., Diamond B. C1q limits dendritic cell differentiation and activation by engaging LAIR-1. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E3160-E3167.
105. Stevens B., Allen N.J., Vazquez L.E., Howell G.R., Christopherson K.S., Nouri N., Micheva K.D., Mehalow A.K., Huberman A.D., Stafford B., Sher A., Litke A.M., Lambris J.D., Smith S.J., John S.W., Barres B.A. The classical complement cascade mediates CNS synapse elimination. Cell 2007, 131:1164-1178.
106. Sturfelt G., Nived O., Sjoholm A.G. Kinetic analysis of immune complex solubilization: complement function in relation to disease activity in SLE. Clin. Exp. Rheumatol. 1992, 10:241-247.
107. Sumida T., Naito A.T., Nomura S., Nakagawa A., Higo T., Hashimoto A., Okada K., Sakai T., Ito M., Yamaguchi T., Oka T., Akazawa H., Lee J.K., Minamino T., Offermanns S., Noda T., Botto M., Kobayashi Y., Morita H., Manabe I., Nagai T., Shiojima I., Komuro I. Complement C1q-induced activation of beta-catenin signalling causes hypertensive arterial remodelling. Nat. Commun. 2015, 6:6241.
108. Takahashi M., Takahashi S., Brade V., Nussenzweig V. Requirements for the solubilization of immune aggregates by complement. The role of the classical pathway. J. Clin. Invest. 1978, 62:349-358.
109. Taylor P.R., Carugati A., Fadok V.A., Cook H.T., Andrews M., Carroll M.C., Savill J.S., Henson P.M., Botto M., Walport M.J. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J. Exp. Med. 2000, 192:359-366.
110. Trendelenburg M. Antibodies against C1q in patients with systemic lupus erythematosus. Springer Semin. Immunopathol. 2005, 27:276-285.
111. Trendelenburg M., Hess C., Kondo-Oestreicher M., Tissot J.D., Spath P., Schifferli J.A. Monomeric complement-activating IgG paraproteins. J. Immunol. 1999, 163:6924-6932.
112. Trendelenburg M., Lopez-Trascasa M., Potlukova E., Moll S., Regenass S., Fremeaux-Bacchi V., Martinez-Ara J., Jancova E., Picazo M.L., Honsova E., Tesar V., Sadallah S., Schifferli J. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol. Dial. Transplant. 2006, 21:3115-3121.
113. Trendelenburg M., Manderson A.P., Fossati-Jimack L., Walport M.J., Botto M. Monocytosis and accelerated activation of lymphocytes in C1q-deficient autoimmune-prone mice. Immunology 2004, 113:80-88.
114. Trendelenburg M., Marfurt J., Gerber I., Tyndall A., Schifferli J.A. Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum. 1999, 42:187-188.
115. Trouw L.A., Bengtsson A.A., Gelderman K.A., Dahlback B., Sturfelt G., Blom A.M. C4b-binding protein and factor H compensate for the loss of membrane bound complement inhibitors to protect apoptotic cells against excessive complement attack. J. Biol. Chem. 2007, 282(September (39)):28540-28548. Epub 2007 Aug 15.
116. Trouw L.A., Blom A.M., Gasque P. Role of complement and complement regulators in the removal of apoptotic cells. Mol. Immunol. 2008, 45:1199-1207.
117. Trouw L.A., Daha N., Kurreeman F.A., Bohringer S., Goulielmos G.N., Westra H.J., Zhernakova A., Franke L., Stahl E.A., Levarht E.W., Stoeken-Rijsbergen G., Verduijn W., Roos A., Li Y., Houwing-Duistermaat J.J., Huizinga T.W., Toes R.E. Genetic variants in the region of the C1q genes are associated with rheumatoid arthritis. Clin. Exp. Immunol. 2013, 173(1):76-83.
118. Trouw L.A., Groeneveld T.W., Seelen M.A., Duijs J.M., Bajema I.M., Prins F.A., Kishore U., Salant D.J., Verbeek J.S., van Kooten C., Daha M.R. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J. Clin. Invest. 2004, 114:679-688.
119. Trouw L.A., Roos A., Daha M.R. Autoantibodies to complement components. Mol. Immunol. 2001, 38:199-206.
120. Trouw L.A., Seelen M.A., Duijs J.M., Benediktsson H., van Kooten C., Daha M.R. Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. Clin. Exp. Immunol. 2003, 132:32-39.
121. Trouw L.A., Seelen M.A., Visseren R., Duijs J.M., Benediktsson H., de Heer E., Roos A., van Kooten C., Daha M.R. Anti-C1q autoantibodies in murine lupus nephritis. Clin. Exp. Immunol. 2004, 135:41-48.
122. Tsacheva I., Radanova M., Todorova N., Argirova T., Kishore U. Detection of autoantibodies against the globular domain of human C1q in the sera of systemic lupus erythematosus patients. Mol. Immunol. 2007, 44:2147-2151.
123. Uwatoko S., Aotsuka S., Okawa M., Egusa Y., Yokohari R., Aizawa C., Suzuki K. Characterization of C1q-binding IgG complexes in systemic lupus erythematosus. Clin. Immunol. Immunopathol. 1984, 30:104-116.
124. Uwatoko S., Aotsuka S., Okawa M., Egusa Y., Yokohari R., Aizawa C., Suzuki K. C1q solid-phase radioimmunoassay: evidence for detection of antibody directed against the collagen-like region of C1q in sera from patients with systemic lupus erythematosus. Clin. Exp. Immunol. 1987, 69:98-106.
125. van der Neut K.M., Schuurman J., Losen M., Bleeker W.K., Martinez-Martinez P., Vermeulen E., den Bleker T.H., Wiegman L., Vink T., Aarden L.A., De Baets M.H., van de Winkel J.G., Aalberse R.C., Parren P.W. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007, 317:1554-1557.
126. van Kooten C., Fiore N., Trouw L.A., Csomor E., Xu W., Castellano G., Daha M.R., Gelderman K.A. Complement production and regulation by dendritic cells: molecular switches between tolerance and immunity. Mol. Immunol. 2008, 45:4064-4072.
127. van Montfoort N., de Jong J.M., Schuurhuis D.H., van der Voort E., Camps M.G., Huizinga T.W., van Kooten C., Daha M.R., Verbeek J.S., Ossendorp F., Toes R.E. A novel role of complement factor C1q in augmenting the presentation of antigen captured in immune complexes to CD8+ T lymphocytes. J. Immunol. 2007, 178:7581-7586.
128. Van Schravendijk M.R., Dwek R.A. Interaction of C1q with DNA. Mol. Immunol. 1982, 19:1179-1187.
129. Vanhecke D., Roumenina L.T., Wan H., Osthoff M., Schaller M., Trendelenburg M. Identification of a major linear C1q epitope allows detection of systemic lupus erythematosus anti-C1q antibodies by a specific peptide-based enzyme-linked immunosorbent assay. Arthritis Rheum. 2012, 64:3706-3714.
130. Walport M.J., Davies K.A., Morley B.J., Botto M. Complement deficiency and autoimmunity. Ann. N. Y. Acad. Sci. 1997, 815:267-281.
131. Wener M.H., Uwatoko S., Mannik M. Antibodies to the collagen-like region of C1q in sera of patients with autoimmune rheumatic diseases. Arthritis Rheum. 1989, 32:544-551.
132. Wisnieski J.J., Jones S.M. Comparison of autoantibodies to the collagen-like region of C1q in hypocomplementemic urticarial vasculitis syndrome and systemic lupus erythematosus. J. Immunol. 1992, 148:1396-1403.
133. Woof J.M., Kerr M.A. The function of immunoglobulin A in immunity. J. Pathol. 2006, 208:270-282.
134. Xu W., Berger S.P., Trouw L.A., de Boer H.C., Schlagwein N., Mutsaers C., Daha M.R., van K.C. Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation. J. Immunol. 2008, 180:7613-7621.
135. Zervou M.I., Vazgiourakis V.M., Yilmaz N., Kontaki E., Trouw L.A., Toes R.E., Bicakcigil M., Boumpas D.T., Yavuz S., Goulielmos G.N. TRAF1/C5, eNOS, C1q, but not STAT4 and PTPN22 gene polymorphisms are associated with genetic susceptibility to systemic lupus erythematosus in Turkey. Hum. Immunol. 2011, 72:1210-1213.